Profile data is unavailable for this security.
About the company
Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd i is engaged in the pharmaceutical and healthcare industry. The Company's segments are Great Southern TCM, Great Commerce, Great Health and Great Medical Care. The Company's Great South TCM includes research, development, manufacturing and sales for Chinese and western medicine, chemical raw medicine, natural drug, biological medicine and intermediates of chemical raw medicine. The Company's Great Health segment includes the research, development, manufacturing and sales of beverages, foods, health products and other products. The Company's Great Commerce segment includes wholesale, retail, import and export for western medicine, Chinese medicine and medical apparatus and instruments. The Great Medical segment is engaged in medical services, traditional Chinese medicine health preservation, modern pension and medical equipment industry.
- Revenue in CNY (TTM)76.83bn
- Net income in CNY4.11bn
- Incorporated1997
- Employees28.05k
- LocationGuangzhou Baiyunshan Pharmaceutical Holdings Co LtdNo. 45 Shamian North StreetLiwan DistrictGUANGZHOU 510130ChinaCHN
- Phone+86 2 066281218
- Fax+86 2 066281229
- Websitehttp://www.gybys.com.cn/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Kangmei Pharmaceutical Co Ltd | 4.93bn | 160.40m | 29.39bn | 4.41k | 182.29 | 4.14 | -- | 5.96 | 0.0116 | 0.0116 | 0.3577 | 0.5117 | 0.34 | 1.40 | 2.43 | 1,118,464.00 | 1.12 | -17.60 | 1.69 | -32.24 | 22.71 | -72.78 | 3.28 | -101.19 | 0.8746 | -- | 0.0465 | -- | 16.60 | -22.17 | 103.81 | -22.83 | -53.51 | -- |
| Hubei Jumpcan Pharmaceutical Co Ltd | 9.67bn | 2.99bn | 29.73bn | 5.23k | 9.89 | 2.08 | -- | 3.07 | 3.26 | 3.26 | 10.54 | 15.51 | 0.5504 | 3.66 | 4.60 | 1,848,716.00 | 17.05 | 16.23 | 22.52 | 20.88 | 79.76 | 82.64 | 30.98 | 24.42 | 3.01 | -- | 0.1275 | 41.76 | 7.32 | 6.02 | 30.04 | 10.83 | -14.70 | 1.11 |
| Tianjin Pharmcetl Da Ren Tang Grp Cp Ltd | 8.15bn | 973.25m | 30.27bn | 4.62k | 24.82 | 3.46 | -- | 3.71 | 1.27 | 1.27 | 10.60 | 9.09 | 0.744 | 3.12 | 3.24 | 1,765,208.00 | 8.71 | 8.96 | 13.06 | 12.80 | 43.68 | 40.82 | 11.70 | 10.67 | 1.62 | -- | 0.1381 | 56.93 | -0.3266 | 5.28 | 14.49 | 11.93 | -4.33 | 42.22 |
| Guangzhou Baiyunshan Phrmcl Hldgs Co Ltd | 76.83bn | 4.11bn | 44.93bn | 28.05k | 11.47 | 1.28 | -- | 0.5848 | 2.52 | 2.52 | 47.25 | 22.68 | 1.01 | 6.70 | 4.70 | 2,739,343.00 | 5.67 | 5.90 | 10.56 | 12.40 | 18.07 | 18.70 | 5.63 | 5.56 | 1.35 | -- | 0.3132 | 30.02 | 6.68 | 12.32 | 2.25 | 3.34 | 27.75 | 12.05 |
| Beijing Tiantan Biological Products Corp | 5.11bn | 1.16bn | 45.78bn | 4.86k | 32.75 | 3.76 | -- | 8.96 | 0.7068 | 0.7068 | 3.10 | 6.15 | 0.3611 | 0.9104 | 171.46 | 1,051,960.00 | 11.18 | 11.71 | 16.00 | 16.50 | 52.26 | 49.39 | 30.97 | 27.71 | 3.41 | -- | 0.0094 | 16.67 | 21.57 | 12.06 | 25.99 | 16.85 | 29.67 | 33.99 |
| Beijing Tongrentang Co Ltd | 17.99bn | 1.72bn | 52.20bn | 16.78k | 30.32 | 3.84 | -- | 2.90 | 1.26 | 1.26 | 13.11 | 9.90 | 0.6079 | 1.23 | 10.82 | 1,072,010.00 | 8.84 | 8.20 | 16.50 | 16.17 | 45.32 | 46.59 | 14.55 | 13.33 | 2.28 | -- | 0.1632 | 30.93 | 16.19 | 4.68 | 16.92 | 8.03 | -12.01 | 13.97 |
| Shanghai Fosun Pharmaceutical (Group) | 40.69bn | 2.01bn | 52.84bn | 40.37k | 28.85 | 1.25 | -- | 1.30 | 0.7525 | 0.7525 | 15.24 | 17.36 | 0.368 | 2.90 | 5.28 | 1,007,829.00 | 2.32 | 4.31 | 3.83 | 7.01 | 46.73 | 50.71 | 6.31 | 10.65 | 0.79 | -- | 0.3818 | 31.92 | -5.81 | 10.69 | -36.04 | -2.50 | 10.95 | -3.34 |
| Holder | Shares | % Held |
|---|---|---|
| Norges Bank Investment Managementas of 31 Dec 2023 | 24.37m | 1.73% |
| E Fund Management Co., Ltd.as of 31 Dec 2023 | 12.57m | 0.89% |
| China Asset Management Co., Ltd.as of 30 Jun 2023 | 8.80m | 0.63% |
| Zhong Ou Asset Management Co., Ltdas of 30 Jun 2023 | 8.68m | 0.62% |
| Bosera Asset Management Co., Ltd.as of 30 Jun 2023 | 8.66m | 0.62% |
| Huatai-PineBridge Fund Management Co., Ltd.as of 31 Dec 2023 | 5.35m | 0.38% |
| China Universal Asset Management Co., Ltd.as of 31 Dec 2023 | 5.10m | 0.36% |
| Hongde Fund Management Co., Ltd.as of 31 Dec 2023 | 4.34m | 0.31% |
| The Vanguard Group, Inc.as of 06 Jun 2024 | 3.96m | 0.28% |
| BlackRock Fund Advisorsas of 06 Jun 2024 | 2.84m | 0.20% |
